Platinum
-
Boehringer Ingelheim
Boehringer Ingelheim
At Boehringer Ingelheim, we hope to alleviate the burden on people living with serious mental illnesses, their care partners, loved ones, and society. To do this, we have made a long-term commitment to invest in research with the aspiration of redefining mental healthcare in partnership with multiple stakeholders and innovative partners. Our ambition is to create a deeper understanding of the drivers of serious mental illnesses and to provide highly effective therapies for those living with these conditions.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com.
Gold
-
RECORDATI SpA & GEDEON RICHTER
RECORDATI SpA & GEDEON RICHTER
Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of innovative medicines to achieve our purpose: improve people’s health and quality of life. We offer high-quality accessible products in various therapeutic areas through our Specialty & Primary Care business, and our Rare Diseases business provides treatments for serious unmet medical needs. Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company, boasting the biggest pharmaceutical research centre in Central Europe. One of its latest achievements is the original antipsychotic, cariprazine, marketed in the US for BD, schizophrenia and aMDD treatment, and in most European countries, for the treatment of schizophrenia in adult patients.
More information about Recordati and Gedeon Richter can be found at www.recordati.com/it/ and www.gedeonrichter.com/en.
Silver
-
Viatris
Viatris
Viatris is global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life’s moments, from birth to the end of life, acute conditions to chronic diseases.
More information about Viatris can be found at www.viatris.com/en.
Exhibitor
-
CEREBRUM VR SRL
CEREBRUM VR SRL
CEREBRUM VR provides cutting-edge, scientifically-driven solutions designed to enhance mental health and well-being. At the heart of our work lies the creation, testing, and development of immersive Virtual Reality technologies tailored for psychiatric rehabilitation, neuropsychological treatments, psychological support, and psychotherapeutic interventions. Our mission is simple: to make therapies more effective and ultimately elevate patients’ quality of life.
More information about CEREBRUM VR can be found at www.cerebrumvr.com.
-
Fidia Farmaceutici S.p.a.
Fidia Farmaceutici S.p.a.
Italian multinational company, with R&D, manufacturing, marketing and sales capabilities, and an extensive product portfolio mainly based on hyaluronic acid (~1,200 patents) in joint care, skin care, eye care, aesthetic care, specialty care and regenerative care. Manufacturing operations – located in Italy – are inspected and approved by major international health authorities, including the US FDA, and comply with the strictest international regulations and safety standards. Fidia extends its global reach through local partners in +120 countries worldwide, as well as wholly owned subsidiaries in USA, Germany, Austria, Spain, France, Russia, Czech Republic, Slovakia, Romania, Poland, Egypt and Middle East.
More information about Fidia Farmaceutici S.p.a can be found at www.fidiapharma.com.
-
STORZ MEDICAL AG
STORZ MEDICAL AG
Founded in 1987, STORZ MEDICAL AG is an independent partner company of the KARL STORZ Group. From our headquarters in Switzerland, we develop innovative shock wave systems. In the 1990s, we discovered the effectiveness of shock waves in the treatment of peripheral neurological diseases such as post-traumatic spasms and polyneuropathy. The first treatment of Alzheimer’s patients with shock waves took place in 2014. In 2018, Transcranial Pulse Stimulation with the NEUROLITH system was the first of its kind to receive approval for the treatment of the central nervous system of Alzheimer’s patients. As a result of this success, neurological diseases such as Parkinson’s, stroke and spinal cord injuries are a focus of our development activities.
More information about STORZ MEDICAL AG can be found at www.storzmedical.com
